Lab Information

Talat Bessissow (MD/MSc)

Investigator
Clinical Research Unit
Department of Medicine (McGill)

Research Profile

 Fundamental: 0%
 Clinical: 100%
 Epidemiology: 0%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords

Crohn's disease • ulcerative colitis • mucosal healing • neoplasia • pathogenesis

Research Interests

My research focuses on the role of mucosal healing in the treatment of inflammatory bowel diseases. I am also looking at identifying factor that predict disease relapse.


Team Members

Name Position

Latest Publications

  1. Abbas, A., Di Fonzo, D. M. P., Wetwittayakhlang, P., Al-Jabri, R., Lakatos, P. L. & Bessissow, T. (2024). Management of ulcerative colitis: where are we at and where are we heading?. Expert review of gastroenterology & hepatology, p. 1-8.
  2. Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
  3. Shehab, M. & Bessissow, T. (2024). Editorial: Advancing care in Crohn's disease-Time to standardise bowel preparation scales. Alimentary pharmacology & therapeutics, vol. 60, p. 1455-1456.
  4. Shehab, M., Alrashed, F., Alsayegh, A., Aldallal, U., Ma, C., Narula, N., Jairath, V., Singh, S. & Bessissow, T. (2024). Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
  5. Shehab, M., Hassan, A., Alrashed, F., Abbas, A., Ma, C., Narula, N., Jairath, V., Singh, S. & Bessissow, T. (2024). Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Inflammatory bowel diseases.
  6. Shehab, M., De Marco, D., Lakatos, P. L. & Bessissow, T. (2024). The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review. Expert opinion on biological therapy, p. 1-14.
  7. Wetwittayakhlang, P., Kotrri, G., Bessissow, T. & Lakatos, P. L. (2024). How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?. Expert opinion on biological therapy, p. 1-9.
  8. Bessissow, T., Narula, N., Ma, C., In, T. S. H., Pone, E., Eberg, M., Jairath, V. & Canadian IBD Research Consortium (2024). Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 56, p. 1690-1697.
  9. Narula, N., Hamam, H., Peerani, F., Bessissow, T., Bressler, B., Dulai, P. S. & Canadian IBD Research Consortium (2024). Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for post-discharge corticosteroid free clinical remission and endoscopic improvement. The American journal of gastroenterology.
  10. Derks, M. E. W., Te Groen, M., van Lierop, L. M. A., Murthy, S., Rubin, D. T., Bessissow, T., Nagtegaal, I. D., Bemelman, W. A., Derikx, L. A. A. P. & Hoentjen, F. (2024). Management of colorectal neoplasia in IBD patients: current practice and future perspectives. Journal of Crohn's & colitis, vol. 18, p. 1726-1735.
More on PubMed 



See also

Card image
Peter
Lakatos


See profile
Card image
Waqqas
Afif


See profile
Card image
Alain
Bitton


See profile
Card image
Paul
Brassard


See profile
Card image
Jean-Pierre
Routy


See profile
Card image
Giada
Sebastiani


See profile